S4 Andarine Selective Androgen Receptor Modulators SARMs Bodybuilding 401900-40-1

S4 Andarine Selective Androgen Receptor Modulators SARMs Bodybuilding 401900-40-1

Synonym	GTx-007, S4
CAS	401900-40-1
Assay	99%
Packing	1kg net/foil bag, 5kg/drum.
Standard	Enterprise Standard
Storage	Shading , Confined Preservation
Usage	For treatment of conditions such as muscle wasting, osteoporosis and benign prostatic hypertrophy
Molecular Fomular	C19H18F3N3O6
Molecular Weight	441.36
MolecularStructure

Andarine, commonly known as S4, is a Selective Androgen Receptor Modulator (SARM) developed by GTx. Like all SARM's S4 was developed in the treatment of muscle wasting diseases with benign prostatic hypertrophy treatment also being high on the list of possible treatment benefits. Andarine is not as strong as some of the other SARM's in terms of an anabolic effect that leads to the promotion of lean muscle tissue increases, but it does appear to have other benefits that can prove to be highly valuable. Being an effective SARM, like most SARM's it is relatively side effect friendly with most users making it an increasingly common option for performance enhancing athletes.

S4 is designed for treating conditions such as muscle wasting, osteoporosis and benign prostatic hypertrophy, using the non-steroidal androgen antagonist bicalutamide as a lead compound.

As an orally active partial agonist for androgen receptors, S-4 is effective in not only maintaining lean body mass but actually increasing it.

SARMS such as S4 can cause muscle growth in the same manner as steroids, however unlike testosterone
and other anabolic steroids, SARMS (as nonsteroidal agents) do not produce the growth effect on prostate and other secondary sexual organs.

The typical dose for cutting is 50 mg for a cycle of 6 to 8 weeks. The cycle should include using the product daily for 5 days and then taking 2 days off for the duration. Tasking the dose every day for the duration of the cycle can result in changes to vision.

Andarine (GTx-007, S4) is an investigational selective androgen receptor modulator (SARM) developed by GTX, Inc for treatment of conditions such as muscle wasting, osteoporosis and benign prostatic hypertrophy, using the non-steroidal androgen antagonist bicalutamide as a lead compound.
In an animal model of benign prostatic hypertrophy, andarine was shown to reduce prostate weight with similar efficacy to finasteride, but without producing any reduction in muscle mass or anti-androgenic side effects.
This suggests that it is able to competitively block binding of dihydrotestosterone to its receptor targets in the prostate gland, but its partial agonist effects at androgen receptors prevent the side effects associated with the anti-androgenic drugs traditionally used for treatment of BPH.

Usage An experimental drug meant to control lipids and increase the level of HDL, or good cholesterol, in the bloodstream.A cell-permeable, thiazolyl compound that acts as a potent, high affinity, PPARd agonist.Exhibits selectivity for PPARd compared t
Usage An experimental drug meant to control lipids and increase the level of HDL, or good cholesterol, in the bloodstream.A cell-permeable, thiazolyl compound that acts as a potent, high affinity, PPARδ agonist.Exhibits selectivity for PPARδ compared to PPARα and PPARγ.Does not exibit any activity against other nuclear or non-nuclear receptors.Reported to increase cholesterol efflux and ABAC1 expression in macrophages, fibroblasts, and intestinal cells.

If you want to know more, please tell me .
China@rawsgear.com
Skype: Steroid-peptide